NL-OMON33984尚未招募2 期
Phase II study of sunitinib (SU011248) in patients with small cell lung cancer who are either chemo-naïve (extensive disease) or have a sensitive relapse - EORTC 08061
European Organisation for Research in Treatment of Cancer (EORTC)0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Histologically proven SCLC
- •Chemo naive or sensitive relapse
- •Measurable disease
- •Normal organ function
排除标准
- •Myocardal infarction, unstable angina, congestive heart failure, cerobrovascular accident or pulmonary embolus within 6 months
- •NCICTCAE grade 3 hemorrhage within 4 weeks
研究者
相似试验
进行中（未招募）
1 期
Phase II study of sunitinib (SU011248) in patients with small cell lung cancer who are either chemo-naïve (extensive disease) or have a sensitive relapsePatients with small cell lung cancer who are either chemo-naïve (extensive disease) or have a sensitive relapse (extensive or limited disease).MedDRA version: 9.1Level: LLTClassification code 10041067Term: Small cell lung cancerEUCTR2006-002485-19-BEEORTC-European Organisation for Research and Treatment of Cancer48
进行中（未招募）
不适用
Phase II study of sunitinib (SU011248) in patients with small cell lung cancer who are either chemo-naïve (extensive disease) or have a sensitive relapsePatients with small cell lung cancer who are either chemo-naïve (extensive disease) or have a sensitive relapse (extensive or limited disease).MedDRA version: 9.1Level: LLTClassification code 10041067Term: Small cell lung cancerEUCTR2006-002485-19-DEEORTC-European Organisation for Research and Treatment of Cancer48
进行中（未招募）
1 期
Phase II study of sunitinib (SU011248) in patients with small cell lung cancer who are either chemo-naïve (extensive disease) or have a sensitive relapseEUCTR2006-002485-19-GBEORTC-European Organisation for Research and Treatment of Cancer48
进行中（未招募）
1 期
Retreatment with sunitinib in patients with metastatic (spread) kidney cancer.EUCTR2012-002891-15-NLVU University Medical Center45
已完成
2 期
Phase II study of sunitinib rechallenge in patients with metastatic renal cell carcinoma.NL-OMON41227Vrije Universiteit Medisch Centrum45